Materials Map

Discover the materials research landscape. Find experts, partners, networks.

  • About
  • Privacy Policy
  • Legal Notice
  • Contact

The Materials Map is an open tool for improving networking and interdisciplinary exchange within materials research. It enables cross-database search for cooperation and network partners and discovering of the research landscape.

The dashboard provides detailed information about the selected scientist, e.g. publications. The dashboard can be filtered and shows the relationship to co-authors in different diagrams. In addition, a link is provided to find contact information.

×

Materials Map under construction

The Materials Map is still under development. In its current state, it is only based on one single data source and, thus, incomplete and contains duplicates. We are working on incorporating new open data sources like ORCID to improve the quality and the timeliness of our data. We will update Materials Map as soon as possible and kindly ask for your patience.

To Graph

1.080 Topics available

To Map

977 Locations available

693.932 PEOPLE
693.932 People People

693.932 People

Show results for 693.932 people that are selected by your search filters.

←

Page 1 of 27758

→
←

Page 1 of 0

→
PeopleLocationsStatistics
Naji, M.
  • 2
  • 13
  • 3
  • 2025
Motta, Antonella
  • 8
  • 52
  • 159
  • 2025
Aletan, Dirar
  • 1
  • 1
  • 0
  • 2025
Mohamed, Tarek
  • 1
  • 7
  • 2
  • 2025
Ertürk, Emre
  • 2
  • 3
  • 0
  • 2025
Taccardi, Nicola
  • 9
  • 81
  • 75
  • 2025
Kononenko, Denys
  • 1
  • 8
  • 2
  • 2025
Petrov, R. H.Madrid
  • 46
  • 125
  • 1k
  • 2025
Alshaaer, MazenBrussels
  • 17
  • 31
  • 172
  • 2025
Bih, L.
  • 15
  • 44
  • 145
  • 2025
Casati, R.
  • 31
  • 86
  • 661
  • 2025
Muller, Hermance
  • 1
  • 11
  • 0
  • 2025
Kočí, JanPrague
  • 28
  • 34
  • 209
  • 2025
Šuljagić, Marija
  • 10
  • 33
  • 43
  • 2025
Kalteremidou, Kalliopi-ArtemiBrussels
  • 14
  • 22
  • 158
  • 2025
Azam, Siraj
  • 1
  • 3
  • 2
  • 2025
Ospanova, Alyiya
  • 1
  • 6
  • 0
  • 2025
Blanpain, Bart
  • 568
  • 653
  • 13k
  • 2025
Ali, M. A.
  • 7
  • 75
  • 187
  • 2025
Popa, V.
  • 5
  • 12
  • 45
  • 2025
Rančić, M.
  • 2
  • 13
  • 0
  • 2025
Ollier, Nadège
  • 28
  • 75
  • 239
  • 2025
Azevedo, Nuno Monteiro
  • 4
  • 8
  • 25
  • 2025
Landes, Michael
  • 1
  • 9
  • 2
  • 2025
Rignanese, Gian-Marco
  • 15
  • 98
  • 805
  • 2025

Rössler, Jochen

  • Google
  • 1
  • 11
  • 3

in Cooperation with on an Cooperation-Score of 37%

Topics

Publications (1/1 displayed)

  • 2023Parkes Weber Syndrome: Contribution of the Genotype to the Diagnosis3citations

Places of action

Chart of shared publication
Döring, Yvonne
1 / 1 shared
Tuleja, Aleksandra
1 / 1 shared
Baumgartner, Iris
1 / 2 shared
Schaller, André
1 / 1 shared
Bernhard, Sarah M.
1 / 1 shared
Maiolo, Massimo
1 / 1 shared
Zweier, Christiane
1 / 1 shared
Vassella, Erik
1 / 1 shared
Vikkula, Miikka
1 / 1 shared
Boon, Laurence M.
1 / 1 shared
Andreoti, Themis-Areti A.
1 / 1 shared
Chart of publication period
2023

Co-Authors (by relevance)

  • Döring, Yvonne
  • Tuleja, Aleksandra
  • Baumgartner, Iris
  • Schaller, André
  • Bernhard, Sarah M.
  • Maiolo, Massimo
  • Zweier, Christiane
  • Vassella, Erik
  • Vikkula, Miikka
  • Boon, Laurence M.
  • Andreoti, Themis-Areti A.
OrganizationsLocationPeople

article

Parkes Weber Syndrome: Contribution of the Genotype to the Diagnosis

  • Döring, Yvonne
  • Tuleja, Aleksandra
  • Baumgartner, Iris
  • Schaller, André
  • Bernhard, Sarah M.
  • Maiolo, Massimo
  • Zweier, Christiane
  • Vassella, Erik
  • Vikkula, Miikka
  • Boon, Laurence M.
  • Rössler, Jochen
  • Andreoti, Themis-Areti A.
Abstract

<jats:sec><jats:title>Objectives:</jats:title><jats:p>Parkes Weber syndrome (PWS) is a rare disorder that combines overgrowth, capillary malformations, and arteriovenous malformations (AVM)/arteriovenous fistulas, for which underlying activating mutations in the ras/mitogen-activated protein kinase/extracellular-signal-regulated kinase signaling pathway have been described. The clinical overlap with Klippel-Trenauny syndrome, associated with mutations in <jats:italic toggle="yes">PIK3CA</jats:italic>, is significant. This case series aimed to elaborate on the phenotypic description of PWS, to underline its clinical overlap with Klippel-Trenauny syndrome and nonsyndromic AVM, and to evaluate the contribution of genotypic characterization to the diagnosis.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>All patients diagnosed with PWS upon enrollment in the Bernese VAScular COngenital Malformations (VASCOM) cohort were included. The diagnostic criteria of PWS were retrospectively reviewed. A next-generation sequencing (NGS) gene panel (TSO500, Illumina) was used on tissue biopsy samples.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>Overall, 10/559 patients of the VAScular COngenital Malformations cohort were initially diagnosed with PWS. Three patients were reclassified as nonsyndromic AVM (Kristen Rat Sarcoma Viral oncogene homolog [<jats:italic toggle="yes">KRAS</jats:italic>], <jats:italic toggle="yes">KRAS</jats:italic>+tumor protein p53, and protein tyrosine phosphatase non-receptor type 11). Finally, 7 patients fulfilled all clinical diagnostic criteria of PWS. Genetic testing was available in 5 PWS patients. Only 1 patient had the classic <jats:italic toggle="yes">RASA1</jats:italic> mutation; another patient had mutations in G protein subunit alpha q (<jats:italic toggle="yes">GNAQ</jats:italic>) and phosphatase and tensin homolog. In a third case, a <jats:italic toggle="yes">PIK3CA</jats:italic> mutation was detected. In 2 patients, no mutations were identified.</jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p>Overgrowth syndromes with vascular malformations are rare and their clinical overlap hampers the classification of individual phenotypes under specific syndrome labels, sometimes even despite genetic testing. To provide optimal patient care, an accurate phenotypic description combined with the identification of molecular targets for precision medicine may be more meaningful than the syndrome classification itself.</jats:p></jats:sec>

Topics
  • impedance spectroscopy
  • size-exclusion chromatography